[德国的全科医生和专家对注意力缺陷/多动障碍 (ADHD) 的药理管理:二次数据分析]
Thomas Grimmsmann1, Wolfgang Himmel2
1Referat Arzneimittel und Methoden, Medizinischer Dienst Mecklenburg-Vorpommern, Schwerin, Germany.
Fortschritte der Neurologie-Psychiatrie
|June 12, 2024
概括
在2008年至2018年期间,在德国,ADHD药物处方从全科医生转向专家. 这一趋势在成年人中更为明显,专家现在管理大多数ADHD处方.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 公共卫生 公共卫生
背景情况:
- 注意缺陷/多动障碍 (ADHD) 是一种普遍存在的儿童疾病,成人诊断越来越多.
- 了解处方模式对于管理ADHD药物获取和护理至关重要.
研究的目的:
- 分析一般医生和专家在德国处方ADHD药物的角色的变化.
- 为了检查从2008年到2018年的ADHD药物处方趋势.
主要方法:
- 来自620家德国诊所的匿名处方数据的二次分析.
- 计算一般医生和专家对ADHD处方的绝对和相对频率.
- 2008年至2018年间处方模式的比较.
主要成果:
- 分析了超过77000名ADHD患者的数据;38%的人接受了药物治疗.
- ADHD 处方从一般医生 (2008 年 59% 的处方) 转移到专家 (2018 年 63%).
- 专家的成年ADHD处方从58% (2008) 增加到80% (2018);儿科处方从38%增加到51%.
结论:
- 在德国,ADHD药物处方从全科医生转向专家发生了显著的转变.
- 这种转变的影响需要进一步调查,考虑到专家的潜在资源限制.
- 优化ADHD护理途径需要评估这一趋势的好处和缺点.
更多相关视频
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
10.3K
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
5.7K
相关概念视频
Attention-Deficit/Hyperactivity Disorder
55
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
55
Drug Therapy
42
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
42
Psychosis: Goals of Pharmacotherapy
123
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
123
Management of Insomnia
244
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
244
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
Parkinson's Disease: Treatment
257
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
257
